Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

Passer à

07499

Supelco

2-Methoxynaphthalene

pharmaceutical impurity standard

Synonyme(s) :

Naproxen Impurity M, Methyl 2-naphthyl ether

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

About This Item

Formule linéaire :
C10H7OCH3
CAS Number:
93-04-9
Poids moléculaire :
158.20
Beilstein:
1859408
Numéro CE :
202-213-6
Numéro MDL:
MFCD00004061
Code UNSPSC :
12352200
ID de substance PubChem :
329748457
Nomenclature NACRES :
NA.24
Le tarif et la disponibilité ne sont pas disponibles actuellement.
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Niveau de qualité

100

Famille d'API

naproxen

Essai

≥98.0% (GC)

Durée de conservation

limited shelf life, expiry date on the label

Impuretés

≤0.5% water

pb

274 °C (lit.)

Pf

70-73 °C (lit.)

Solubilité

H2O: soluble (completely)

Densité

1.064 g/mL at 25 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article
P560793693PHR1332
L-Proline

P8865

L-Proline

L-Proline from non-animal source, meets EP, USP testing specifications, suitable for cell culture

P5607

L-Proline

L-Proline certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

93693

L-Proline

L-Proline Pharmaceutical Secondary Standard; Certified Reference Material

PHR1332

L-Proline

biological source

non-animal source

biological source

non-animal source

biological source

-

biological source

-

form

crystalline powder

form

powder

form

-

form

-

impurities

endotoxin, heavy metals, residual solvents, tested

impurities

endotoxin, tested

impurities

-

impurities

-

assay

≥98.5%

assay

98.5-101.0% dry basis

assay

-

assay

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

cleaning products
cosmetics
flavors and fragrances
food and beverages
personal care

application(s)

pharmaceutical (small molecule)

technique(s)

cell culture | mammalian: suitable

technique(s)

cell culture | mammalian: suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1040

Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1165

Naproxen sodium, Pharmaceutical Secondary Standard; Certified Reference Material

1457301

Naproxen, United States Pharmacopeia (USP) Reference Standard

N0250000

Naproxen, European Pharmacopoeia (EP) Reference Standard

Y0000399

Naproxen (racemic), European Pharmacopoeia (EP) Reference Standard

Y0000631

Naproxen impurity L, European Pharmacopoeia (EP) Reference Standard

1457403

Naproxen sodium, United States Pharmacopeia (USP) Reference Standard

1457312

Naproxen Related Compound A, United States Pharmacopeia (USP) Reference Standard

1457425

Naproxen Related Compound L, United States Pharmacopeia (USP) Reference Standard

08129

6-Methoxy-2-naphthol, pharmaceutical impurity standard

79584

2-Ethyl-6-methoxynaphthalene, pharmaceutical impurity standard

80713

(1RS)-1-(6-Methoxynaphthalen-2-yl)ethanol, pharmaceutical impurity standard

82170

(R)-Naproxen, pharmaceutical impurity standard

07506

(S)-Naproxen ethyl ester, pharmaceutical impurity standard

80822

(S)-Naproxen methyl ester, pharmaceutical impurity standard

80816

(2S)-2-(5-Chloro-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80821

(2S)-2-(5-Iodo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

80818

(2S)-2-(5-Bromo-6-methoxynaphthalen-2-yl)propanoic acid, pharmaceutical impurity standard

07503

2-Bromo-6-methoxynaphthalene, pharmaceutical impurity standard

07547

6-Methoxy-2-naphthoic acid, pharmaceutical impurity standard

BP435

Naproxen, British Pharmacopoeia (BP) Reference Standard

1457436

Naproxen Related Compound G, United States Pharmacopeia (USP) Reference Standard

PHR2254

Naproxen 1,2,3 Propanetriol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2256

Naproxen 1,3-Butylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2219

Naproxen 1,2 Propylene Glycol Esters, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2248

Naproxen 2,3-Butylene Glycol Ester, pharmaceutical secondary standard

PHR2257

Naproxen Isopropyl Ester, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2524

Naproxen Impurity N, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2525

Naproxen Impurity M, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2527

Naproxen Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2526

Naproxen Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2520

Naproxen Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2519

Naproxen Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2518

Naproxen Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2523

Naproxen Related Compound L, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2530

rac-Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2517

Naproxen Related Compound K, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2521

Naproxen Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2522

Naproxen Impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2528

Naproxen Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2529

Naproxen Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation markEnvironment
GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H319,H411

Classification des risques

Aquatic Chronic 2 - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

  • Fiche des caractéristiques

    • Faites votre choix parmi les versions les plus récentes :

    Certificats d'analyse (COA)

    Lot/Batch Number
    BCCC6260
    BCBW1605
    BCBR1347V
    BCBR1347

    Vous ne trouvez pas la bonne version ?

    Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

    Rechercher un(e) COA

    Déjà en possession de ce produit ?

    Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

    Consulter la Bibliothèque de documents

    Les clients ont également consulté

    Slide 1 of 6

    1 of 6

    L-Proline United States Pharmacopeia (USP) Reference Standard

    USP

    1568506

    L-Proline

    L-Proline-15N ≥95 atom % 15N, 98% (CP)

    Sigma-Aldrich

    608998

    L-Proline-15N

    D-Proline ReagentPlus®, ≥99%

    Sigma-Aldrich

    858919

    D-Proline

    L-Phenylalanine EMPROVE® EXPERT, Ph. Eur., JP, USP

    SAFC

    1.07267

    L-Phenylalanine

    Sigma-Aldrich

    Sigma-Aldrich

    M6899

    Murashige and Skoog Basal Salts with minimal organics

    L-Threonine

    SAFC

    T4071

    L-Threonine

    Marie Couturier et al.
    The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
    The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
    David Saadoun et al.
    Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
    The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
    Salvatore Petta et al.
    Hepatology (Baltimore, Md.), 59(5), 1692-1705 (2014-04-03)
    We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype.
    Michael P Manns et al.
    Gastroenterology, 147(2), 366-376 (2014-04-15)
    MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
    Ewa Sawosz et al.
    International journal of molecular sciences, 16(10), 25214-25233 (2015-10-30)
    Our previous studies revealed that graphene had anticancer properties in experiments in vitro with glioblastoma multiforme (GBM) cells and in tumors cultured in vivo. We hypothesized that the addition of arginine or proline to graphene solutions might counteract graphene agglomeration
    Afficher tous les articles scientifiques apparentés

    Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

    Contacter notre Service technique